Decision Resources, Inc., June 2010, Pages: 54
. The research-based pharmaceutical industry has developed a host of treatments for both chronic and acute viral infections. Faced with growing expenditures on these medicines, governments and other payers
Datamonitor, July 2010, Pages: 67
-Detailed ten-year sales forecasts for marketed hepatitis B drugs in each of the seven major markets and Turkey
-Review of opinions of key hepatitis B opinion leaders on future market developments
John Wiley and Sons Ltd, July 2011, Pages: 480
Section III: HIV Nucleoside Reverse Transcriptase Inhibitors
7. Discovery and Development of Tenofovir Disoproxil Fumarate
Erik De Clercq
8. Discovery and Development of Apricitabine
Susan Cox, John
Business Monitor International, Dec 2011, Pages: 81
to the introduction of Cote d'Ivoire into the rankings for the first time.
Key Trends & Developments
- Zimbabwe's fight against HIV and tuberculosis (TB) will be affected by a significant reduction in the Global
John Wiley and Sons Ltd, Jan 2011, Pages: 520
This book is a compilation of summarized analytical methods designed to serve the needs of pharmacologists, toxicologists, and other allied health professionals involved the development, use
Business Monitor International, Nov 2008, Pages: 74
the potential to boost the market value beyond the forecast US$1.53bn. The device, presently under development in Japan, will be used to indicate if an HIV/AIDS patient is allergic to an antiretroviral. In fact
Decision Resources, Inc., Dec 2005, Pages: 79
blockbusters is one approach, though the shift taking place in the therapeutic areas ripe for blockbuster development means that some companies must adjust their core competencies.
In this report, we identify
Business Monitor International, Sep 2008, Pages: 89
and support for the local private sector has inclined it to cooperate with global players, particularly in developing vaccines, as it seeks to wean itself from export dependency over the longer term. Also
